SHATTUCK LABS INC (STTK) Stock Price & Overview
NASDAQ:STTK • US82024L1035
Current stock price
The current stock price of STTK is 6.42 USD. Today STTK is up by 2.72%. In the past month the price increased by 25.88%. In the past year, price increased by 775.85%.
STTK Key Statistics
- Market Cap
- 459.415M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.77
- Dividend Yield
- N/A
STTK Stock Performance
STTK Stock Chart
STTK Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to STTK. When comparing the yearly performance of all stocks, STTK is one of the better performing stocks in the market, outperforming 99.49% of all stocks.
STTK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to STTK. STTK has a great financial health rating, but its profitability evaluates not so good.
STTK Earnings
STTK Forecast & Estimates
13 analysts have analysed STTK and the average price target is 10.2 USD. This implies a price increase of 58.88% is expected in the next year compared to the current price of 6.42.
For the next year, analysts expect an EPS growth of 31.21% and a revenue growth -100% for STTK
STTK Groups
Sector & Classification
STTK Financial Highlights
Over the last trailing twelve months STTK reported a non-GAAP Earnings per Share(EPS) of -0.77. The EPS increased by 48.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.62% | ||
| ROE | -59.24% | ||
| Debt/Equity | 0 |
STTK Ownership
STTK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About STTK
Company Profile
Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. The company is headquartered in Austin, Texas and currently employs 40 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The firm is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. The company is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Company Info
IPO: 2020-10-09
SHATTUCK LABS INC
500 W. 5Th Street, Suite 100
Austin TEXAS 78703 US
CEO: Taylor Schreiber
Employees: 40
Phone: 18003166660
SHATTUCK LABS INC / STTK FAQ
What does STTK do?
Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. The company is headquartered in Austin, Texas and currently employs 40 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The firm is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. The company is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Can you provide the latest stock price for SHATTUCK LABS INC?
The current stock price of STTK is 6.42 USD. The price increased by 2.72% in the last trading session.
Does STTK stock pay dividends?
STTK does not pay a dividend.
How is the ChartMill rating for SHATTUCK LABS INC?
STTK has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for STTK stock?
13 analysts have analysed STTK and the average price target is 10.2 USD. This implies a price increase of 58.88% is expected in the next year compared to the current price of 6.42.
Would investing in SHATTUCK LABS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on STTK.
What is SHATTUCK LABS INC worth?
SHATTUCK LABS INC (STTK) has a market capitalization of 459.42M USD. This makes STTK a Small Cap stock.